What if you could activate macrophages to engulf and destroy cancer cells? Meet Pheast Therapeutics and principal founder Amira Barkal, MD/PhD, whose PhD research uncovered a macrophage checkpoint with incredible potential against #ovariancancer . medium.com/@Pheast_inc/un… #BuiltOnBenchling

An exciting surprise today! Thanks, Nasdaq, for featuring Pheast Therapeutics

Honored to be featured on Nasdaq! Thanks so much to our investors Catalio Capital Management, ARCH, Alexandria Venture Investments & @R2_Ventures✨

Startup Pheast raises $76M to bite cancer's 'don't eat me' signals bizjournals.com/sanfrancisco/n… via San Francisco Business Times

“Investors have an appetite for Pheast. The women-led immuno-oncology startup just closed out a $76 million series A funding round, fueling its development of therapies targeting cancer's “don’t eat me” signal.”Thank you, Gabrielle Masson @fiercebiotech!
fiercebiotech.com/biotech/eating…

'In particular, Pheast is hoping to make changes to treatment options for patients with ovarian and breast cancers who have seen lackluster responses to existing immunotherapies.' So true BioSpace ✨ biospace.com/article/pheast…

#Cancer cells employ multiple mechanisms to evade the immune system. Scientists at Pheast Therapeutics found a new one and they’re turning the discovery into a new #immunotherapy . The Stanford University spinout now has $76M for its work. medcitynews.com/2022/04/cancer… #biotech #startups

Check out what San Francisco Business Times reporter Ron Leuty has to say about our co-founder & interim CEO Amira Barkal, MD/PhD and our company:

bizjournals.com/sanfrancisco/n… Ravi Majeti Stanford Stem Cell #biotech

In the days leading up to our launch @Pheast_inc co-founder and interim CEO Amira Barkal, MD/PhD connected with Endpoints News editor Kyle LaHucik to discuss the work we’re doing with CD24. Curious for more? Don’t forget to read the full article here: endpts.com/weissmans-lab-…

Very excited to introduce you to Pheast Therapeutics, a Catalio-created immuno-oncology company, founded by Drs. Irv Weissman & Amira Barkal at Stanford University. Pheast is developing therapies targeting cancer's “don’t eat me” signals fiercebiotech.com/biotech/eating…

Pheast Therapeutics co-founder and interim CEO Dr. Amira Barkal recently sat down with @FierceBioTech to discuss our launch and some of the work we’re doing to fight cancer. Check out the full post here: fiercebiotech.com/biotech/eating…

Thrilled to have been selected as a 2022 Weintraub awardee. Thank you to the Weintraub Graduate Student Award selection committee, to the one and only (yet Twitter-less) Irv Weissman, and all of my mentors at Stanford Stem Cell Stanford Medicine and Brigham and Women's Medicine Residents for all of the support!

My lab at Stanford is hiring. We work on engineering new cancer immunotherapies and understanding their activity in early phase trials. Open postdoc positions as well as a technician with animal experience. Contact me if interested! Please retweet!